insights_auto
Why is KSPHF down 4,93%?
Dive Deeperchevron_right
KSPHF:OTCMKTS
Kissei Pharmaceutical Co Ltd
USD 24,50
arrow_downward
-4,93%(-1,27) 1D
1 Okt., 16:00:00 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for KSPHF...
Open
USD 24,50
High
USD 24,50
Low
USD 24,50
Mkt. cap
172,21 mjd
Avg. vol.
0,00
Volume
609,00
52-wk high
USD 31,90
52-wk low
USD 24,50
Beta
13,91
Shares outstanding
46,54 m
No. of employees
2 k
Open
USD 24,50
High
USD 24,50
Low
USD 24,50
Mkt. cap
172,21 mjd
Avg. vol.
0,00
Volume
609,00
52-wk high
USD 31,90
52-wk low
USD 24,50
Beta
13,91
Shares outstanding
46,54 m
No. of employees
2 k
News stories
From web sources and news partners
Simply Wall Street
·
32 minute gelede
With EPS Growth And More, Sound Group (NASDAQ:SOGP) Makes An Interesting Case
Business Insider
·
3 uur gelede
The NYSE's Most Famous Floor Trader Says AI Can't Take His Job
Seeking Alpha
·
1 uur gelede
One Trade, Two Markets, One Hidden Correction (NYSEARCA:RSP)
Yahoo Finance
·
1 uur gelede
Nasdaq Hits Fresh Ground on Chip and Software Strength as Dow, Small Caps Lag for the Week
Profile
Kissei Pharmaceutical is a pharmaceutical company based in Matsumoto, Nagano, Japan. Products discovered or developed by Kissei include:
Difelikefalin
Fostamatinib
Linzagolix
Mitiglinide
Remogliflozin etabonate
Silodosin
Tranilast
In March 2020, Kissei and CG Oncology, Inc. announced an exclusive license, development, and commercialization agreement for CG's oncolytic immunotherapy drug CG0070. The agreement covered Japan, South Korea, Taiwan, and other Asian countries, but not China. Wikipedia
About Kissei Pharmaceutical Co Ltd
CEOMutsuo Kanzawa
Employees1,79 k
Founded09 Aug. 1946
HeadquartersMatsumoto, Nagano-prefektuur, Japan
SectorPharmaceutical industry
Websitekissei.co.jp